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Background: Limited data are available on the risk ratios for fatal cardiovascular disease (CVD) outcome from gout
and chronic kidney disease (CKD) in non-diabetic individuals.
Methods: Nationwide population-based retrospective prospective study with a 5-year follow-up to investigate the
association between physician-diagnosed gout and CKD in non-diabetics aged 50 and above who had no
pre-existing serious CVD and the subsequent risk of death from CVD. Hazard ratios (HR) of CVD mortality were
adjusted for gender, age, smoking- and alcoholism-related diagnoses, hypertension, hyperlipidemia, atrial fibrillation
and Charlson’s comorbidity index score.
Results: A case cohort (n=164,463) having gout and a control cohort (n= 3,694,377) having no gout were formed.
The prevalence of gout in this study was 4.26% whereas that of gout plus CKD was 8.17%. Male to female ratio
among the individuals with gout was 3.2:1. The relative risk (RR) of subsequent cardiovascular mortality between
the case and control cohort was 1.71 (95% confidence interval (CI), 1.66-1.75). The presence of CKD in nondiabetic
subjects with no gout (control group) has a RR of CVD mortality at 3.05 (95% CI, 2.94-3.15). The presence of gout
has protective effect on subjects with CKD with a RR of 1.84 (95% CI, 1.71-1.98). As compared with individuals with
no gout, the adjusted HR (aHR) for CVD mortality among the individuals with gout was 1.10 (95% CI 1.07-1.13). In a
Cox model, when compared with subjects having neither gout nor CKD, the aHR in subjects with no gout but with
CKD is 1.76 (95% CI, 1.70-1.82); in subjects with gout but without CKD, 1.10 (1.07-1.13); interestingly, the aHR is
attenuated in subjects with concomitant gout plus CKD which is 1.38 (1.29-1.48).
Conclusions: Among non-diabetic individuals aged 50 years or above who had no preceding serious CVD, those
with gout were 1.1 times more likely to die from CVD as were individuals without gout. The presence of gout
appears to attenuate the risk of subsequent CV mortality in subjects with CKD. Further studies should focus on
finding an explanation for the protective effect of gout on CV mortality in patients with CKD.* Correspondence: victorkok@live.asia.edu.tw; horng@db.csie.ncu.edu.tw
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Gout is commonly seen in clinics and its prevalence has
increased in recent years. It is estimated that approximately
6.1 million adults in the United States have had been diag-
nosed with gout [1]. Gout or hyperuricemia has long been
suspected to increase the risk of cardiovascular disease [2-
5]. A recent report from Taiwan using data from a single
institute obtained via a health screening program demon-
strated that the adjusted hazard ratio of cardiovascular
mortality was 1.97 (95% CI 1.08, 3.59) for subjects with
gout as compared with subjects with normouricemia [3].
Death from cardiovascular disease (CVD) encompassed
coronary heart disease (CHD), which was manifested by
myocardial infarction, angina pectoris, heart failure, and
coronary death; cerebrovascular disease as manifested by
stroke and/or transient ischemic attack; peripheral artery
disease and aortic atherosclerosis with thoracic or abdom-
inal aortic aneurysm. It is noted that cardiovascular events
in the Asian-Pacific countries consist of relatively fewer
from coronary heart disease (CHD) but relatively more
from stroke events [6].
Type 2 diabetes has been considered by some as having a
similar negative effect on coronary heart disease (CHD) [7-
10]. In a population-based 18-year follow-up study of
Finnish subjects, type 2 diabetes without prior myocardial
infarction and prior myocardial infarction without diabetes
resulted in a similar risk of CHD mortality among both
men and women. When less stringent criteria for prior his-
tory of CHD were used (myocardial infarction or ischemic
ECG changes or angina pectoris), type 2 diabetes carried a
larger risk than having a prior history of CHD, particularly
in women [7]. Thus when diabetes is present together with
gout, diabetes per se is a significant confounding factor with
respect to the cardiovascular mortality. Based on the
current observations as stated above, we therefore have
investigated, in the absence of any influence from diabetes,
whether individuals with gout carry a higher risk of mortal-
ity from cardiovascular cause.
Similar to the observations that diabetes mellitus is a
risk factor contributing to CVD mortality, patients with
chronic kidney disease also have increased risk of cardio-
vascular mortality[11-14]. Therefore it is interesting to
investigate the association between gout with or without
CKD and the subsequent CVD mortality.
We therefore carried out a nationwide population-
based study to examine the association between
physician-diagnosed gout in non-diabetic subjects aged
50 years or above and with or without concomitant
CKD and subsequent CVD mortality.
Methods
Database
This study was designed as a population-based retro-
spective cohort study using the Taiwan National HealthInsurance Research Database (NHIRD). Taiwan National
Health Insurance (NHI) program started in March 1,
1995. As of 2007, 98.4% of Taiwan’s population (22.96
million individuals) were enrolled in this program. The
NHIRD contains a number of large computerized data-
bases that include registration files and original data on
claims’ reimbursement that are derived from the insur-
ance system held by the Bureau of National Health In-
surance of Taiwan (BNHI); these databases are
maintained by the National Health Research Institutes
(NHRI) of Taiwan and are provided to researchers for
academic research purposes. These data files are de-
identified by scrambling the identification codes of both
the individuals and medical facilities; information on
individuals is then sent to the National Health Research
Institutes and forms the original files of NHIRD. This
study adhered to strict confidentiality guidelines that are
in accordance with the regulations regarding personal
electronic data and privacy protection. As the data files
consist of unidentified secondary data, the study was
exempted from a full review by the Institutional Review
Board.
We utilized the databases for admissions and out-
patient visits for the study cohorts, both of which in-
clude information on individuals’ characteristics, and
include sex, date of birth, date of admission, date of dis-
charge, dates of visits, admission diagnoses, and out-
patient visit diagnoses.
Study cohorts
From the year 2003, we pinpointed individuals who were
aged 50 and above from the total enrollees available on
the databases who had sought medical services from the
Taiwan National Health Insurance system. Subjects with
incomplete data or null value (5.6% of the total enrollees
in 2003) were excluded. Subjects who had suffered from
a severe form of cardiovascular disease or diseases dur-
ing the preceding year were also excluded. The severe
cardiovascular diseases included malignant hypertension,
hypertensive nephropathy, myocardial infarction or any
form of congestive heart failure as well as having had
coronary artery bypass surgery or percutaneous trans-
luminal coronary angioplasty. Additionally, intracerebral
hemorrhage, intracranial hemorrhage, occlusion/stenosis
of the precerebral arteries and occlusion of cerebral ar-
teries were also excluded (see Appendix: Table 4). By ex-
cluding these individuals, we ensured that the control
group and case group did not have existing severe
comorbidities such as ischemic heart disease, an old
cerebrovascular accident and carotid arterial stenosis. Fi-
nally, we excluded every remaining subject that also had
either type 1 or type 2 diabetes.
Using the diagnostic variables in admission and out-
patient data files from the NHI database, we sorted the
Kok et al. BMC Cardiovascular Disorders 2012, 12:108 Page 3 of 9
http://www.biomedcentral.com/1471-2261/12/108study case subjects into those with gout-related diagno-
ses, i.e., showing codes under 274 of the International
Classification of Disease, 9th Revision, Clinical Modifica-
tion (ICD-9-CM) (see Appendix: Table 5)[15] and those
without such a diagnosis. Under ICD-9-CM code 274,
individuals with gouty arthropathy (274.0), gouty
nephropathy (274.1), gouty iritis (274.89), gouty tophi
(274.8), and uric acid nephrolithiasis (274.11) were
included. Validation of these physician-diagnosed gout
was ensured by verification that there were at least three
separate outpatient visits by the same individual. We use
gout and gout-related diagnoses interchangeably in this
paper.
Demographic data such as age, gender, smoking-related
diagnosis, alcoholism-related diagnosis, and Charlson’s
comorbidity index (CCI) were collected for further adjust-
ment. Any comorbid medical conditions were identified
using their standard ICD-9-CM codes and were used to
calculate cumulatively the established Charlson-Deyo
comorbidity index for each individual. The Charlson-Deyo
comorbidity index score, adapted from the Charlson index
for use with ICD-9-CM coded administrative databases,
contains 17 weighted categories related to chronic con-
comitant diseases and is able to predict the subsequent 1-
year mortality among inpatients. Each category has a score
between 1 and 6 points (1 point for myocardial infarction,
congestive heart failure, peripheral vascular disease, cere-
brovascular disease, dementia, chronic pulmonary disease,
rheumatological disease, peptic ulcer disease, mild liver dis-
ease, and diabetes without organ damage; 2 points for dia-
betes with organ damage, hemiplegia or paraplegia, severe
renal disease, any malignancy including leukemia and
lymphoma; 3 points for severe liver disease; 6 points for
metastatic solid tumor and HIV infection), and sum of
these scores is regarded as a measure of the burden of
comorbidity[16,17]. To avoid double-counting and possible
over-adjustment in a regression model, chronic kidney dis-
ease was excluded from the CCI score.
After the stringent selection process of the subject indivi-
duals as stated above, ultimately the study cases were non-
diabetic individuals with gout, aged 50 and above, who had
no severe hypertensive, cerebrovascular or cardiovascular
disease. In order to elucidate the impact of chronic kidney
disease on the analyses, both case and control groups were
dichotomized into two groups by the status of CKD.
Chronic kidney diseases are defined based on ICD-9-cm
codes given for at least three times in the reimbursement
data. Cases were then followed up until year 2007. The risk
for CVD mortality associated with gout was evaluated using
relative risk (RR) calculation and hazard ratio (HR) in Cox
proportional hazards regression.
The control group in this study consists of those with-
out any gout-related diagnosis after having gone through
the same aforementioned selection process.Survival data
We checked the National Death Registry maintained by
the Department of Health of Taiwan for death from car-
diovascular disease and well as to confirm the survival of
each individual case within the two cohort populations
included that make up our study. The status and causes
of death were ascertained from the Taiwan National
Death Registry 2003–2007.
Statistical analysis
SAS statistical package (SAS System for Windows, ver-
sion 8.2, SAS Institute, Cary, NC, USA) was used for
pre-analysis data file merging and other data manage-
ment before statistical analysis. Statistical analysis was
performed using SPSSsoftware (version 17.0, SPSS Inc.,
Chicago, Illinois, USA). All statistical tests were two-
sided. Values of p < 0.05 were considered statistically
significant. The risk of death due to CVD that was asso-
ciated with gout was evaluated using Cox proportional
hazards analysis. All Cox regression models included the
following covariates: gender, age, smoking-related diag-
nosis as a surrogate for cigarette smoking history and
alcoholism-related diagnoses as a surrogate for chronic
alcoholism history, hypertension, hyperlipidemia, atrial
fibrillation and Charlson’s co-morbidity index (CCI)
score. To avoid double-counting and thus over-
adjustment during multivariable regression model, in
subjects with chronic kidney disease, CCI score did not
consider chronic renal failure as a comorbidity.
Hazard ratios with a 95% confidence interval were cal-
culated. The relative risks (RR) of CVD mortality for
both genders were then calculated and analyzed by Chi-
square test (2x2).
Results
Based on the NHIRD, there were 20,439,3939 enrollees
during the whole year 2003. After excluding enrollees
data containing null value (or missing data) or incom-
plete data which was approximately 5.6% of the total
enrollees’ record, 19,289,770 were retained as the source
for study. Out of these, there were 4,439,936 individuals
who were aged 50 year-old or older. A total of 104,389
individuals with preexisting severe CVD during the pre-
ceding year of this case-cohort study were then
excluded. Of the remaining 4,335,547 individuals,
476,707 were excluded next because they were suffering
from either type 1 or type 2 diabetes. This left 3,858,840
individuals of which 164,436 (4.26% of the non-diabetic
individuals aged 50 or over and without a preexisting ex-
cluding condition), had gout. Finally, the individuals
without gout forming the control group totaled
3,694,377 (Figure 1). The proportion of CKD in both
groups is different, with higher proportion of CKD in
the case group, approximately 8.2% versus 1.4% in the
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CKD or the reverse) suggested by this cross-sectional
data.
The male to female ratio among the subjects with gout
was calculated as 3.2:1 and consisted of 125,311 men
and 39,152 women. The case group as compared with
the control group without gout, has higher prevalence of
hypertension (27.8% versus 10.1% in the control group),
hyperlipidemia (5.8% versus 1.4%), smoking-related diag-
nosis (10.4% vs. 6.7%), alcoholism-related diagnosis
(1.8% vs. 0.7%) and uremia (1.4% vs. 0.5%) (Table 1).
All subjects in case and control groups were followed
up to the end of year 2007. A total of 74,367 subjects in
the control group and 5,650 individuals in the case
group were identified as dying of cardiovascular disease
during follow-up. The relative risk of CVD mortality
among subjects with gout was calculated to be 1.71 (95%
CI = 1.66 – 1.75) (Table 2). In the control group,Figure 1 Flowchart illustrating the selection of cases and controls and
cardiovascular disease; NHIRD, National Health Insurance Research Databassubjects with chronic kidney disease (CKD) have ap-
proximately 3-fold risk of dying from CVD than subjects
without CKD (RR = 3.05, 95% CI = 2.94-3.15). However
this magnitude of risk is markedly diminished in the
case group subjects with CKD, i.e., subjects with both
gout and CKD, with RR of 1.84, 95% CI 1.71-1.98
(Table 2).
The crude hazard ratio (HR) of CVD mortality among
the case group was found to be 1.69 with 95% CI from 1.7
to 1.7 (p value <0.0001). After adjustments made for gender,
age, smoking-related diagnosis, alcoholism-related diagno-
sis, hypertension, hyperlipidemia and Charlson’s co-
morbidity index, the adjusted HR was 1.10 with 95% CI of
1.07 to 1.13 (p value <0.0001). This confirms that gout
alone in this studied population of nondiabetic subjects
aged 50 or above contributes statistically significantly, as a
risk factor to subsequent death from CVD cause. In an-
other words, a person in the case group is 1.1 times asfollow up. Abbreviations: CKD, chronic kidney disease; CVD,
e.
Table 1 Patient demographics and disease and treatment characteristics
Characteristic Overall Case group Control group P-value
3,858,840 164,463 [%] 3,694,377 [%]
With chronic kidney disease 66,476 13,445 [8.18] 53,031 [1.44] <.0001
Without chronic kidney disease 3,792,364 151,018 3,641,346
Age group, years
50-59 1,750,009 54,586 [33.19] 1,695,423 <.0001
60-69 1,097,797 50,413 [30.65] 1,047,384
70-79 734,932 45,041 [27.39] 689,891
≥80 276,102 14,423 [8.77] 261,679
Sex
Male 1,863,738 125,311 [76.19] 1,738,427 [47.06] <.0001
Female 1,995,102 39,152 1,955,950
Comorbidities
Hypertension 419,678 45,693 [27.8] 373,985[10.1] <.0001
Hyperlipidemia 60,744 9,521 [5.8] 51,223 [1.4] <.0001
Smoking-related diagnosis 262,913 17,183 [10.4] 245,730 [6.7] <.0001
Alcoholism-related diagnosis 28,305 2,891 [1.8] 25,414 [0.7] <.0001
Uremia 21,526 2,228 [1.4] 19,298 [0.5] <.0001
Charlson’s comorbidities Index score†
0 3,099,342 106,542 2,992,800 0.0336
1 494,593 35,179 459,414
2 178,885 14,215 164,670
3 50,181 5,264 44,917
4 16,497 1,858 14,639
5 5,752 659 5,093
6 2,360 261 2,099
7 1,269 101 1,168
8 6,321 204 6,117
9 2,384 100 2,284
10+ 1,256 80 1,176
Follow-up in years
0 63,220 2,682 60,538 -
1 65,186 4,115 61,071
2 67,987 4,446 63,541
3 67,136 4,484 62,652
4 3,519,426 144,228 3,375,198
5 75,885 4,508 71,377
†Mann-Whitney U test.
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son with a person in the control group (Table 3, model 1).
In the case cohort with gout, the presence of CKD has a
crude HR of 1.99 of subsequent CVD mortality when com-
pared with subjects with gout but no CKD. The adjusted
HR is 1.40 (95% CI, 1.29 – 1.51) (Table 3, model 2).
In subjects without gout, chronic kidney disease
(CKD) has higher crude HR of 3.35 (95% CI, 3.24 –3.47) of subsequent death from CVD in the next 5 years.
After adjustments made in the multivariable Cox regres-
sion model, the adjusted HR is 1.74 (95% CI, 1.68 –
1.81) (Table 3, model 3).
The interplay from gout and CKD to the subsequent
death from CVD can be illustrated from the fourth Cox
model in Table 3 where when compared with “Control
without CKD” (subjects with neither gout nor CKD), the
Table 2 Relative risks of dying from CVD by the presence









Control 3,694,377 74,367 1 [Reference] -
Case 164,463 5,650 1.71 1.66-1.75
Control with or without CKD
No CKD 3,641,346 71,209 1 [Reference] -
With CKD 53,031 3,158 3.05 2.94-3.15
Case with or without CKD
No CKD 151,018 4,853 1 [Reference] -
With CKD 13,445 797 1.84 1.71-1.98
CVD cardiovascular disease; CI confidence interval; Chi-square test (2x2) was
used for the RR calculation.
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CKD”; 1.10 (95% CI, 1.07 – 1.13) in cases with gout but
without CKD; 1.38 (95% CI, 1.29 - 1.48) in cases with gout
plus concomitant CKD. After adjustment was made
for gender, age, smoking-related diagnosis, alcoholism-
related diagnosis, hypertension, hyperlipidemia, atrial fibril-
lation and Charlson’s comorbidity index score, the adjusted
HR is attenuated from 1.76 (in subjects without gout but
with CKD) to 1.38 (in subjects with gout and with CKD)
when gout is present concomitantly with CKD.Table 3 Hazard ratios of subsequent death from CVD (2005.1
Cox models Crude HR 95%CI SE
Low Up
Model 1
Control group (without gout) 1 - - -
Case group (with gout) 1.69 1.65 1.74 0.01
Model 2
Gout but no CKD 1 - - -
Gout plus CKD 1.99 1.85 2.14 0.04
Model 3
Control without CKD 1 - - -
Control with CKD 3.35 3.24 3.47 0.02
Model 4
Control without CKD 1 - - -
Control with CKD 3.36 3.24 3.48 0.02
Gout but no CKD 1.62 1.58 1.67 0.01
Gout plus CKD 3.21 2.99 3.44 0.04
*Adjustments were made in these Cox models for gender, age, smoking and alcoho
Charlson’s co-morbidity index (CCI) score. To avoid double-counting (over-adjustme
renal failure as a comorbidity.
CVD cardiovascular disease; CI confidence interval; CKD chronic kidney disease. HR h
analysis; SE standard error.Discussion
Cardiovascular disease (CVD) mortality is the leading cause
of death in most developed countries. Coronary heart dis-
ease (CHD), one of the four diagnostic categories of CVD,
accounts for approximately one third to one half of CVD
cases. It is well established that diabetes mellitus (DM) and
chronic kidney disease (CKD) are considered as two most
important CHD risk equivalents [7,12,14,18]. Therefore,
when this study is to test whether gout is an emerging risk
factor for CVD, the confounding factors from DM and
CKD should be tackled first using a different study design.
To our knowledge, this study is the first of its kind to
examine the association of gout and CVD mortality using a
nationwide population-based cohort study with an ad hoc
design to deliberately exclude patients with DM and then
stratify cohorts into groups with or without CKD at the be-
ginning of the study. The advantage of excluding all
patients with type 2 diabetes before forming study cohorts
precludes the necessity in the future resorting to statistical
adjustments which would be suboptimal in terms of
evidence-based approach. This study also excludes patients
with pre-existing major cardiovascular and/or cerebrovas-
cular co-morbidities in the preceding one year of the study.
The strength of this study includes the complete follow-up
with no drop-outs due to nationwide registration of the
subjects’ use of any medical resource in the country.
Our results show that the distribution of cases of gout





- 1 - - - -
<.0001 1.10 1.07 1.13 0.01 <.0001
- 1 - - - -
<.0001 1.40 1.29 1.51 0.04 <.0001
- 1 - - - -
<.0001 1.74 1.68 1.81 0.02 <.0001
- 1 - - - -
<.0001 1.76 1.70 1.82 0.02 <.0001
<.0001 1.10 1.07 1.13 0.02 <.0001
<.0001 1.38 1.29 1.48 0.04 <.0001
lism-related diagnoses, hypertension, hyperlipidemia, atrial fibrillation and
nt), in subjects with chronic kidney disease, CCI score did not consider chronic
azard ratio which was calculated by Cox proportional time-to-event survival
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(Table 1). This difference of the prevalence of gout in dif-
ferent age group can be explained by the fact that subjects
who live longer are less likely afflicted with gout problems
or its related complications. The strengths of this study is
using smoking-related diagnosis, alcoholism-related diag-
nosis, Charlson-Deyo comorbidity index score to avoid
the occurrence of recall bias from interview-based or
questionnaire-based study design [16,17].
Our results show that gout is an independent risk fac-
tor for CVD mortality. The relative risk for CVD mortal-
ity as the cause of death in the next five years is 1.71
with a narrow 95% confidence interval of 1.66 to 1.75.
The crude hazard ratio for subsequent death from CVD
in subjects with gout is 1.69 (95% CI, 1.65-1.74). After
adjustment made for gender, age, smoking-related diag-
nosis, alcoholism-related diagnosis, hypertension, hyper-
lipidemia, atrial fibrillation and Charlson’s comorbidity
index score, the multivariable Cox regression analysis
still shows a statistically significant hazard ratio of 1.10
(95% CI, 1.07-1.13). This confirms that gout alone mod-
estly increases the risk for subsequent CVD mortality in
the next five years.
Review of the literature on the association between
gout and CHD or CVD mortality discloses four relevant
studies of heterogeneous study design and different
follow-up time [3,5,19,20]. The Health Professionals Fol-
low Up Study and the Multiple Risk Factor Intervention
Trial included Caucasian male subjects only[5,19]. The
HR for cardiovascular mortality in the latter trial was not
statistically significant exhibiting an adjusted HR of 1.21
(95% CI, 0.99-1.49) [19]. A single institution observa-
tional study in Taiwan using health screening program
subjects shows that the adjusted HR for CVD death is
1.97 (95% CI, 1.08-3.59) in participants with gout [3].
This study had short follow up time (mean, 56 months)
and did not make adequate adjustment for significant
confounders such as medical comorbidities. A recently
published study from Singapore which included only
Chinese aged 45 to 74 years with gout has demonstrated
an HR for CHD mortality of 1.38 (95% CI, 1.10 - 1.73)
[20]. Nevertheless, this study necessitated the partici-
pants to recall a history of previously diagnosed gout
as their standard definition of gout. Furthermore, the
Singaporean study was not able to adequately adjust for
the participants’ coexisting medical co-morbidities. Our
present study was able to use physician-diagnosed gout
as the basis of disease confirmation and adding Charlson
comorbidity index score for adjustment in the multivari-
able Cox regression.
This study shows that gout coexists with CKD in
8.18% in subjects with gout whereas only 1.44% of sub-
jects in the control group have had CKD. No causal rela-
tionship can be extrapolated from the current studydesign. Our study demonstrated that in subjects with no
gout, the presence of CKD exhibited a RR of 3.05 (95%
CI, 2.94 – 3.15) of CVD mortality. It is surprising to
note that gout attenuates the association between CKD
and the risk for CVD mortality in patients with CKD
coexisting with gout demonstrating a RR of 1.84 (95%
CI, 1.71 - 1.98). In a Cox proportional hazard model
with multivariable adjustment, when compared to con-
trol without CKD (subjects with neither gout nor CKD),
the group of subjects with no gout but with CKD has an
adjusted HR of 1.76 (95% CI, 1.70 – 1.82), however, the
coexistence of gout plus CKD pulls down the adjusted
HR to 1.38 (95% CI, 1.29 - 1.48) (Table 3).
Our study is the first to show that the presence of gout
may have protective effects against cardiovascular mor-
tality in patients with chronic kidney disease. The pos-
sible explanations for this observation may not be the
gout per se but on the medications used for managing
gout such as urate-lowering drug, allopurinol [21-25].
Allopurinol, a xanthine oxidase inhibitor, is the most
commonly used medication for urate-lowering purpose
in gout and hyperuricemia. Preclinical data have shown
that allopurinol has protective effect on both myocardial
and renal ischemia-reperfusion injury [22,24]. In an ob-
servation study, allopurinol was associated with a lower
risk of all-cause mortality (HR 0.78; 95% CI 0.67, 0.91)
in subjects with hyperuricemia [23]. A small-scale pro-
spective open-label randomized trial carried out in
patients with chronic kidney disease with patients ran-
domly assigned to treatment with allopurinol 100 mg/
day (n = 57) or to continue the usual therapy (n = 56),
allopurinol decreases C-reactive protein and slows down
the progression of renal disease in patients with CKD
[21]. In addition, allopurinol reduces cardiovascular and
hospitalization risk in these subjects. Allopurinol treat-
ment reduces risk of cardiovascular events in 71% com-
pared with standard therapy with an adjusted HR for
new cardiovascular events such as congestive heart fail-
ure, cerebrovascular accidents, ischemic coronary
events, and peripheral arteriopathy, at 0.29 (95% CI, 0.09
– 0.86) [21]. Therefore, our present study with complete
follow up demonstrating attenuated risks for subsequent
cardiovascular mortality by the coexistence of gout and
CKD may be explained by allopurinol prescribed in
patients with gout among other explanatory variables.
Further studies should examine the association between
allopurinol use and the cardiovascular mortality.
One of the potential limitations of this study is
whether the diagnosis of physician-diagnosed gout pos-
sibly contains pseudogout and other crystalline arthri-
tides. Because each gout case was identified as having
made three separate visits (same ICD code given on at
least three clinical encounters) and this is a strict criter-
ion for physician-diagnosed gout adopted by almost all
Table 4 The ICD-9-cm codes for severe forms of
cardiovascular diseases (Continued)
404.93 Hypertensive heart and chronic kidney disease Unspecified
414.04 Coronary atherosclerosis of artery bypass graft
V45.81 Aortocoronary bypass status
V45.82 Percutaneous transluminal coronary angioplasty status
410 Acute myocardial infarction
411 Other acute and subacute forms of ischemic heart disease
429.79 Certain sequelae of myocardial infarction, not elsewhere
classified
398.91 Rheumatic heart failure (congestive)
428.0 Congestive heart failure, unspecified
518.83 Chronic respiratory failure
415.19 Pulmonary embolism and infarction Other
573.4 Other disorders of liver: Hepatic infarction
431 Intracerebral hemorrhage
432.0 Intracranial hemorrhage: nontraumatic epidural hemorrhage
432.9 Other and unspecified intracranial hemorrhage Unspecified
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classification bias is considered very modest due to rela-
tive ease of making a gout diagnosis by physicians in
Taiwan [26]. We do not have access to the relevant bio-
chemical datasets and lifestyle personal histories such as
abdominal obesity, psychosocial factors, consumption of
fruits and vegetables, and regular physical activity. This
is because individual identities are not available due to
the de-identification of the individuals within the NHI
databases. Another potential limitation is that data for
medication and treatment for gout and CKD and the ad-
herence to treatment were too complex to incorporate
in the covariate analyses. Furthermore, the impact of un-
diagnosed diabetes mellitus cannot be excluded because
diabetes and metabolic syndrome is related to both gout
and cardiovascular mortality [27-29].
In summary, the results clearly show that, among indi-
viduals without diabetes who have no major cardio-
cerebrovascular disease, gout presents a higher risk of
death from cardiovascular causes.intracranial hemorrhage
430 Subarachnoid hemorrhage
433 Occlusion and stenosis of precerebral arteries
434 Occlusion of cerebral arteries
997.02 Iatrogenic cerebrovascular infarction or hemorrhage
ICD-9-cm International Classification of Diseases, 9th revision; clinical
modification, 6th edition






274.10 gouty nephropathy, unspecifiedConclusions
Among non-diabetic individuals aged 50 years or above
who had no preceding serious CVD, those with gout
were 1.1 times more likely to die from cardiovascular
disease as were individuals without gout in the next five
years. Confounding factors such as the impact of un-
diagnosed diabetes mellitus cannot be excluded. In con-
clusion, we suggest that gout although significant is not
a powerful risk factor for future cardiovascular mortality
as evidenced from this population-based nationwide ob-
servation study with a prospective cohort. The protective
effect against cardiovascular mortality evidenced by the
attenuation of risk in subjects with gout plus chronic
kidney disease in this study should be further explored
and confirmed in the future studies.Appendix
Table 4 The ICD-9-cm codes for severe forms of
cardiovascular diseases
ICD-9-cm Disease
402.00 Hypertensive heart disease Malignant Without heart failure
402.01 Hypertensive heart disease Malignant With heart failure
402.11 Hypertensive heart disease Benign With heart failure
402.91 Hypertensive heart disease Unspecified With heart failure
404.00 Hypertensive heart and chronic kidney disease Malignant
404.01 Hypertensive heart and chronic kidney disease Malignant
404.03 Hypertensive heart and chronic kidney disease Malignant
404.13 Hypertensive heart and chronic kidney disease Benign
404.91 Hypertensive heart and chronic kidney disease Unspecified
274.11 uric acid nephrolithiasis
274.19 other gouty nephropathy
274.8 gout with other manifestations
274.81 gouty tophi of ear
274.82 gouty tophi of heart
274.89 other manifestations
274.9 gout , unspecified
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